bluuebunny/crossref_metadata_2025_split huggingface dataset:
Heart rate and mortality in myocardial infarction: incremental or bimodal correlation?
Authors: Biasco L , Foster-Witassek F , Radovanovic D , Dittli P , Tersalvi G , Rickli H , Roffi M , Eberli F , Jeger R , Erne P , Pedrazzini G B 
Published: October 2022

Abstract

Introduction
Risk prediction scores adopted in acute coronary syndromes use incremental models to estimate mortality for heart rate (HR) above 60 bpm. Nonetheless, a non-linear, bimodal relationship, with higher event rates at low or high HR, has been described, potentially hampering risk prediction accuracy.

Purpose
Our aim was to assess the prognostic impact of bradycardia, defined as admission HR &lt;50 bpm, in myocardial infarction (MI) among patients enrolled in a large nationwide registry.

Methods
Data of patients enrolled between 1999 and 2021 stratified by admission HR were retrospectively analysed. The primary endpoint was in-hospital mortality. The secondary endpoint was a composite of death, cerebrovascular event, and reinfarction. Associations between HR and outcomes were assessed at univariate and multivariable logistic regression analyses, then verified after sequential propensity-score matchings among HR groups.

Results
51001 patients (median age 66 years, IQR 56–76) were included. Crude estimates showed a bimodal distribution of primary and secondary endpoints with peaks at low and high HR. Association of HR &lt;50 bpm with mortality was recognised only at primary multivariable logistic regression analysis (OR 1.49; 95% CI 1.01–2.13 p=0.038) but not at multiple sensitivity analyses after exclusion of patients on negative chronotropic therapy. Three sequential propensity-score matching were performed among patients with HR &lt;50 bpm at admission and those with HR 50–75 bpm, HR 76–100 bpm and HR &gt;100 bpm at admission, identifying 1159, 1159 and 1158 matched pairs, respectively. After propensity-score matching, rates of primary and secondary endpoints equalled among groups with HR &lt;100 bpm.

Conclusions
Bradycardia (HR &lt;50 bpm) at admission in patients with MI identified a group with higher crude rate of adverse events. Nonetheless, the signal supporting an independent association between bradycardia at admission and short-term mortality is weak and was not confirmed after correction for relevant baseline differences by propensity score matching. These findings support the hypothesis that lower HR might not be causative for the worse outcomes, but rather serves as a marker of underlying morbidity.

Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): The AMIS Plus registry is funded by unrestricted grants from the Swiss Heart Foundation and from Abbot AG, Amgen AG, AstraZeneca AG, Bayer (Schweiz) AG, Biotronik AG, Boston Scientific AG, B. Braun Medical AG, Daiichi-Sankyo/Lilly AG, Cordis Cardinal Health GmbH, Medtronic AG, Novartis Pharma Schweiz AG, Sanofi-Aventis (Schweiz) AG, SIS Medical AG, Terumo AG, Vascular Medical GmbH, all in Switzerland, and the Swiss Working Group for Interventional Cardiology. The sponsors did not play any role in the design, data collection, analysis, or interpretation of data.
Prevalence and outcomes of peripheral artery disease in a real-world cohort of patients with acute coronary syndrome: insights from the prospective SPUM registry
Authors: Denegri A , Magnani G , Kraler S , Wenzl F , Raeber L , Gencer B , Mach F , Nanchen D , Matter C M , Luescher T F 
Published: October 2022

Abstract

Background
Despite substantial improvement in secondary preventive therapy, the burden of recurrent cardiovascular (CV) events remains high. Peripheral artery disease (PAD), is a potential marker of increased residual ischemic risk in acute coronary syndrome (ACS) patients suggesting greater net clinical benefit from intensified individualized therapy.

Purpose
We aimed to assess the prevalence and cardiovascular (CV) outcomes of peripheral arterial disease (PAD) in 4'787 patients with acute coronary syndromes (ACS) in the Swiss prospective multicenter SPUM study.

Methods
PAD was defined according to international guidelines. The composite primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), i.e., stroke, myocardial infarction (MI) and death at 1 year. Adjusted Cox proportional hazards regression models were used to estimate the risk associated with PAD and outcomes.

Results
Out of 4'787 ACS patients, 285 patients (6.0%) had PAD. These patients were older (70.1±10.6 vs 63.3±12.4, p&lt;0.001), presented all traditional CV risk factors (all p&lt;0.001) and were more likely to have a complex history of CV disease, such as previous MI (24.3% vs 11.4%, p&lt;0.001), prior percutaneous (32.3% vs 13.8%, p&lt;0.001) or surgical (12.6% vs 3.5%, p&lt;0.001) coronary revascularization. PAD-patients presented also higher levels of inflammatory biomarkers, such as hs-CRP, and GRACE 2.0 score (all p&lt;0.001). At 1 year, patients with PAD had a higher rate of MACCE compared to those presenting without PAD. Rates of the individual components of the primary endpoint and CV-death were all significantly higher in patients with PAD (all p&lt;0.001), except for a numerical increase in MI (5.3% vs 3.3%, p=0.060). This enhanced risk persisted after adjustment for differences in baseline characteristics, with a 53% (Adj. HR 1.53, CI95% 1.14–2.08, p=0.005) increase in MACCE. In spite of high-intensity anti-thrombotic therapy, PAD patients presented the same rate (Adj. HR 1.03, CI95% 0.68–1.54, p=0.901) of major bleeding events at 1 year.

Conclusions
Among a real-world cohort of ACS patients, the coexistence of PAD, a very-high CV risk phenotype, is associated with significantly increased rates of MACCE, but no difference in major bleeding events. These observations might help clinicians to further stratify this very-high risk population and to identify patients who may derive the greatest benefit from more intense secondary prevention therapies.

Funding Acknowledgement
Type of funding sources: None.
Prognostic impact of aborted cardiac arrest in patients with acute myocardial infarction
Authors: Presume J , Gomes D , Strong C , Tralhao A , Aguiar C , Trabulo M , Almeida M , Ferreira J , Mendes M 
Published: October 2022

Abstract

Background
Aborted cardiac arrest (ACA) during the acute ischaemic phase is a relatively frequent but often undervalued complication of acute myocardial infarction (AMI). The aim of this study was to evaluate the clinical and prognostic impact of aborted cardiac arrest in AMI patients and investigate its correlation with infarct size.

Methods
We conducted a single-centre retrospective study enrolling consecutive patients admitted for AMI, from January 2016 to December 2018. ACA was defined as the need for advanced life support measures and defibrillation, either out-of-hospital or in-hospital, up until culprit vessel revascularisation. Infarct size was estimated using peak serum troponin T, impact on left ventricular ejection fraction (LVEF ≤50%) and echocardiographic wall motion index (WMI). Clinical outcomes included cardiogenic shock (SCAI C or more), need for mechanical circulatory support (MCS), major bleeding events (BARC ≥3) during in-hospital phase and all-cause mortality during follow-up.

Results
A total of 571 patients were included (65±13 years old, 72% male). Overall, 237 had anterior STEMI, 39 patients (6,8%) suffered ACA (21 out of hospital), 60 progressed into cardiogenic shock throughout the hospitalisation, 7 needed MCS, and 52 had BARC ≥3 bleeding. During a mean follow-up of 32 months, 96 patients died.
ACA was significantly associated with higher peak serum troponin T (4802 [1950; 9420] vs 2659 [555; 6708] ng/L – p=0.004), higher proportion of patients with reduced or mildly reduced LVEF (60% vs. 36.5%, p=0.018) and higher WMI (1.7 [1.4; 2.3] vs. 1.5 [1.2; 1.8], p=0.016). Moreover, ACA was also associated with higher risk of cardiogenic shock occurrence (64.1% vs. 6.6%, p&lt;0.001 – OR 25.357 (12.115–53.073)), higher need for MCS (7.9% vs 0.8%, p&lt;0.001 – OR 11.271 (2.427–52.343)) and higher incidence of BARC ≥3 bleeding events (28.2% vs. 8.4%, p&lt;0.001 – OR 4.705 (2.185–10.128)) – Table 1.
On univariate Cox regression, ACA showed significant association with all cause death, which remained highly significant after multivariable adjustment (OR 2.431 (1.181; 5.002); p=0.016).

Conclusion
The occurrence of aborted cardiac arrest in patients with AMI was associated with increased morbidity and mortality. This may be driven by a larger area of arrhythmia prone ischemic myocardium.

Funding Acknowledgement
Type of funding sources: None.
Prognostic and diagnostic impact of new pathophysiology-based categorization of type 1 and type 2 myocardial infarction: data from the French RICO survey
Authors: Yao H , Putot A , Chague F , Maza M , Bichat F , Cottin Y , Zeller M 
Published: October 2022

Abstract

Background
A new classification of type 1 and 2 myocardial infarction (MI) derived from the fourth universal definition of MI (UDMI) has been recently proposed, based on pathophysiology of coronary artery disease (CAD),. We assessed the impact of this new MI categorization on epidemiology and outcomes.

Methods
Retrospective study including all consecutive patients hospitalized for an acute MI in a multicenter database (RICO). MI was defined according to current UDMI. Rates and outcomes of T1MI and T2MI were addressed according to the new classification.

Results
Among the 4573 patients included on our study, 3710 patients (81.1%) were initially diagnosed with T1M1 and 863 (18.9%) with T2MI. After reclassification, 96 T2MI patients were moved into the T1MI category. Out of the remaining 767 patients with T2MI, 567 underwent coronary angiography, and were adjudicated as type 2A MI (68.6%) with obstructive CAD, and type 2B MI (31.4%) without obstructive CAD.
When compared with T1MI and T2BMI, T2AMI patients had worse in-hospital outcomes, including heart failure (p&lt;0.001), recurrent infarction (p&lt;0.048) and mechanical complications such as mitral insufficiency (p=0.001). The 3 groups (T1AMI, T2AMI and T2BMI) had similar all-cause and cardiovascular death rates, with a trend for a higher all-cause mortality in T2AMI patients.
Kaplan-Meier one-year survival curves showed higher all-cause and cardiovascular causes mortality in T2AMI patients compared to T1MI and T2BMI (p&lt;0.001). In multivariate Cox regression, type of MI was independent predictor of death.

Conclusion
Our large observational multicenter study shows major disparities in mortality according to type of MI and support the relevance of the new MI classification to improve risk classification. Our findings may will help identifying specific phenotypes and considering personalized diagnostic and management strategies.

Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Agence Régionale de Santé (ARS) de Bourgogne Franche-ComtéRegional Council of Bourgogne Franche-Comté.
Prognostic impact of newly diagnosed atrial fibrillation and episode characteristics in patients with acute coronary syndrome
Authors: Bor W L , Azzahhafi J , Di Maio N , Van Der Sangen N M R , Rayhi S , Chan Pin Yin D R P P , Peper J , Ten Berg J M 
Published: October 2022

Abstract

Background/Introduction
Newly diagnosed atrial fibrillation (AF) frequently occurs during acute coronary syndrome (ACS). In contrast to known AF, little is known about the prognostic and therapeutic implications of new AF.

Purpose
To evaluate the prognostic impact of newly diagnosed and known AF in patients with ACS. Furthermore, we evaluated the association of episode characteristics of new AF with clinical outcomes: early vs late occurrence, short vs long duration, post-CABG occurrence, and OAC treatment.

Methods
This analysis was performed within the prospective, multicentre, FORCE-ACS registry which studies ACS patients in the Netherlands. All ECGs during index ACS admission were retrospectively examined for the occurrence of AF. Patients were classified as no, new, or known AF. New AF episodes were described regarding early or late occurrence, duration of the episode, and post-CABG occurrence, and OAC prescription at discharge was evaluated. The primary outcome was MACE, a composite of death, myocardial infarction and stroke. Secondary outcomes include the separate MACE components and bleeding. Crude and adjusted outcomes were evaluated by univariable and multivariable Cox regression.

Results
3902 patients were included of which 299 (10.2%) had new and 367 (9.4%) had known AF. Major adverse cardiac events happened significantly more in both new and known AF patients than in patients without AF (22.2%, 17.4%, and 9.2%, p&lt;0.001). Ischemic stroke occurred significantly more in new AF but not in known AF patients, compared to patients without AF (3.5% vs 0.9% vs 1.1%). After one year follow-up, a total of 234 patients (6.3%) deceased, of whom 138 in the group without AF (4.6%), and significantly more in the groups with new AF (n=59, 15.9%), and known AF (n=37, 10.8%). The timing of onset of the AF episode showed no significant association with clinical outcomes. Longer duration of the episode, however, was associated with increased MACE (HR 2.0, 95% CI 1.2–3.1) and all-cause mortality (HR 2.0, 95% CI 1.2–3.4). Episodes of new AF that occurred post-CABG were associated with less MACE (HR 0.31, 95% CI 0.14–0.67) and all-cause mortality (HR 0.20, 95% CI 0.07–0.55). No significant association between OAC treatment and MACE nor any of its separate components was found.

Conclusion
Newly diagnosed atrial fibrillation in acute coronary syndromes is associated with worse clinical outcomes than known or no atrial fibrillation. Longer episodes were associated with worse outcomes than short episodes. Post-operative new AF was associated with better outcomes than non-post-operative new AF.

Funding Acknowledgement
Type of funding sources: None.
Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina – a prospective Norwegian cohort
Authors: Svingen G , Pedersen E K R , Meyer K , Softeland E , Tell G , Ueland P M , Nygaard O K 
Published: October 2022

Abstract

Background and methods
Recent guidelines have included glycated haemoglobin (HbA1c) ≥48 mmol/L as a diagnostic criterion for diabetes mellitus (DM) in addition to plasma glucose (PG) concentrations, mainly based on the relationship between hyperglycemia and microvascular disease [1]. However, increased HbA1c may stem not only from hyperglycemia, and the risk association between HbA1c and long-term survival in patients with stable coronary heart disease and HbA1c ≥48 mmol/L but no previous DM according to PG is uncertain. We explored the relationship between HbA1c and survival among patients with and without DM who were evaluated for stable angina in the period 2000–2004. Endpoints were obtained from the Norwegian Cause of Death Registry.

Results
In total, 4164 patients were evaluated by cardiac cathetherization, of whom 576 patients (13.8%) had DM (median HbA1c 55 mmol/L) according to self-report and/or baseline PG concentrations. Of the remaining 3588 patients 1026 had HbA1c ≥48 mmol/L; however, HbA1c did not correlate with the HOMA2 insulin resistance index or fasting PG in these patients. During median (25–75 percentile) follow-up time of 14.0 (12.1–15.4) years a total of 1328 patients (31.9%) died, of whom 582 from cardiovascular causes. In patients with DM according to PG, HbA1c trended towards positive associations with all-cause and CVD mortality when adjusted for age and gender (HRs (95% CIs) 1.13 (0.99–1.28) and 1.16 (0.98–1.39) per 1SD, respectively). However, HbA1c was not associated with survival in either the group of patients without DM and HbA1c &lt;48 mmol/L (median HbA1c 38 mmol/L) (HRs (95% CIs) 0.99 (0.92–1.06) and 0.96 (0.86–1.08) for all-cause and CVD mortality, respectively) or patients without DM but having HbA1c ≥48 mmol/L (median HbA1c 53 mmol/L) (HRs (95% CIs) 0.99 (0.88–1.12) and 1.04 (0.88–1.22)).

Conclusion
In patients evaluated for stable angina pectoris about two decades ago, almost a third of patients with no history of DM according to PG still had HbA1c concentrations indicating DM according to current guidelines. Including these patients in the DM category yielded similar percentages of patients with DM as observed in recent populations with stable coronary disease [2]. However, as opposed to what we observed in patients with DM, HbA1c did not show any association with very long-term survival among patients without DM. Our findings therefore question the use of HbA1c in the diagnosis of DM, especially in terms of risk assessment for longevity among patients with chronic coronary syndrome.

Funding Acknowledgement
Type of funding sources: None.
0/1h-algorithm using a new high-sensitivity cardiac troponin I assay for early diagnosis of myocardial infarction
Authors: Koechlin L , Boeddinghaus J , Lopez-Ayala P , Nestelberger T , Wussler D , Twerenbold R , Zimmermann T , Wildi K , Miro O , Martin-Sanchez J , Keller D , Christ M , Buser A , Rubini Gimenez M , Mueller C 
Published: October 2022

Abstract

Background
The clinical performance of the novel high-sensitivity cardiac troponin I EXL (hs-cTnI-EXL) assay is unknown so far.

Purpose
We aimed to validate the clinical performance of the hs-cTnI-EXL assay and to derive and validate an hs-cTnI-EXL-specific 0/1h-algorithm for the early diagnosis of myocardial infarction (MI).

Methods
This multicenter study included patients presenting to the emergency department with symptoms suggestive of myocardial infarction. Central adjudication of final diagnoses was performed by two independent cardiologists using all clinical information including cardiac imaging twice: first, using serial hs-cTnI-Architect (primary analysis) and second, using serial hs-cTnT-Elecsys (secondary analysis) concentrations in addition to those clinically used (hs)-cTn. Hs-cTnI-EXL was measured at presentation and at 1h. The primary objective was to directly compare diagnostic accuracy quantified by the area under the receiver-operating-characteristic curve (AUC) of hs-cTnI-EXL, hs-cTnI-Architect and hs-cTnT-Elecsys. Secondary objectives included the derivation and validation of an hs-cTnI- EXL-specific 0/1h-algorithm.

Results
MI was the adjudicated final diagnosis in 204/1454 (14%) patients. At presentation, the AUC for hs-cTnI-EXL was 0.94 (95% CI, 0.93–0.96), being comparable to hs-cTnI-Architect (0.95; 95% CI, 0.93–0.96) and hs-cTnT-Elecsys (0.93; 95% CI, 0.91–0.95; Figure 1). In the derivation cohort (n=813), an optimal hs-cTnI-EXL-0/1h-algorithm was rule-out of MI with &lt;9ng/L if onset of chest pain &gt;3h or &lt;9ng/L & 0h-1h-change &lt;5ng/L, and rule-in with ≥160ng/L or 0h-1h-change ≥100ng/L. In the validation cohort (n=345), this hs-cTnI-EXL-0/1h-algorithm also performed well: rule-out in 56% of patients, negative predictive value 99.5% (95% CI, 97.1–99.9), sensitivity 97.8% (95% CI, 88.7–99.6), rule-in in 9% of patients, positive predictive value 83.3% (95% CI, 66.4–92.7), specificity 98.3% (95% CI, 96.1–99.3; Figure 2). Secondary analyses confirmed the findings using adjudication including serial measurements of hs-cTnT-Elecsys.

Conclusions
Hs-cTnI-EXL has comparable diagnostic performance to the currently best-validated hs-cTnT/I assays.

Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Swiss National Foundation, Swiss Heart Foundation
Soluble suppression of tumorigenicity associated to post-procedural no-or-slow-reflow phenomenon in ST-elevation myocardial infarction
Authors: Sondergaard F , Beske R , Frydland M , Helgestad O , Jensen L O , Holmvang L , Engstroem T , Moeller J E , Hassager C 
Published: October 2022

Abstract

Background
Over the last decades, the prognosis for patients with ST-elevation myocardial infarction (STEMI) has improved due to primary percutaneous coronary intervention (pPCI). However, no-or-slow-reflow phenomenon after pPCI constrains this benefit. Suppression of tumorigenicity (sST2) is released from vascular endothelial cells in response to myocyte stretch and increased sST2 level in the initial phase of STEMI is a useful prognostic biomarker for predicting mortality and heart failure (HF).

Purpose
To explore the association of sST2 with post-procedural no-or-slow-reflow phenomenon in patients with STEMI.

Method
During a 1-year period in 2015/2016, the study included consecutive STEMI patients from two heart centers who underwent acute coronary angiography (CAG). Blood samples including sST2 levels were collected at admission and before angiography and/or revascularization. Post-procedural coronary flow was assessed according to thrombolysis in myocardial infarction (TIMI) classification for STEMI. We divided patients into two groups: TIMI 0,1 and 2 as no-or-slow-reflow, and TIMI 3 as normal reflow. Both troponin I and troponin T were used and therefore combined and grouped into 10th percentile levels. The association between sST2 and TIMI flow was explored using multiple logistic regression adjusted for age, gender, hypercholesterolemia, diabetes, hypertension, cardiogenic shock, time from onset of symptoms to CAG, and troponin levels.

Results
In total, 1,789 consecutive patients with verified STEMI and available TIMI flow classification were included in the analysis. Of these, 1,693 (94.6%) classified as normal reflow and 96 (5.4%) as no-or-slow-reflow. The proportion of male sex was similar (1,253 (74%) vs 67 (70%), p=0.36) in the two groups. No-or-slow-reflow patients were older (median 68 years (IQR 57–75) vs median 63 years (IQR 54–72), p=0.02) and more likely to develop cardiogenic shock (22 (23%) vs 146 (8.6%), p&lt;0.001). The troponin level was similar in the two groups (no-reflow: 5.50 (2.00, 8.00) vs normal reflow: 5.00 (3.00, 7.00), p=0.38). In the regression model, sST2 was independently associated with post-procedural no-or-slow-flow (two-fold sST2 increase: OR 1.37 (1.09, 1.70, p=0.006)).

Conclusion
In patients with STEMI, sST2 level at admission before coronary angiography is associated with the post-procedural no-or-slow-reflow phenomenon.

Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Righospitalets Forskningsfond AND Lundbeck Foundation